Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Insulin glargine is a long-acting human insulin analog used to improve glycemic control in adults and pediatric patients with diabetes under product-specific age criteria. Current U.S. products include U-100 and U-300 formulations as well as biosimilar insulin glargine products.
read more about insulin glargine ...Insulin glargine increases glucose uptake in skeletal muscle and fat and decreases glucose production in the liver. After subcutaneous injection, its formulation produces prolonged basal insulin activity. It also reduces lipolysis and proteolysis and increases protein synthesis.
Insulin glargine is used as basal insulin in type 1 and type 2 diabetes under product-specific labeling. Patients with type 1 diabetes also use a rapid-acting or short-acting insulin for meal coverage. Insulin glargine is not recommended for treatment of diabetic ketoacidosis.
Insulin glargine is injected subcutaneously once daily at the same time each day. Dosing is individualized according to the product concentration, diabetes type, prior insulin regimen, metabolic needs, and blood glucose results. U-100 and U-300 products follow separate switching and titration instructions.
Hypoglycemia can be life-threatening. Other concerns include hypokalemia, severe hypersensitivity, medication errors, lipodystrophy, localized cutaneous amyloidosis, and fluid retention or heart failure with thiazolidinediones. Insulin glargine is not given intravenously and is not mixed with other insulins.
Insulin glargine is a long-acting human insulin analog used for basal insulin treatment.
Current U-100 and U-300 products are administered subcutaneously once daily.
No. They contain different insulin concentrations and follow product-specific dosing and switching instructions.
No. Current labeling directs against mixing or diluting insulin glargine products.
Glargine Insulin. https://www.ncbi.nlm.nih.gov/books/NBK557756/. Date Accessed October 5, 2026.
Insulin Glargine (rDNA Origin) Injection: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a600027.html. Date Accessed October 5, 2026.
LANTUS (Insulin Glargine) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5e07a0c-7e14-4756-9152-9fea485d654a. Date Accessed October 5, 2026.
SEMGLEE (Insulin Glargine-yfgn) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8cf5544f-87d6-468b-f6ae-898b1fdb5d80. Date Accessed October 5, 2026.
TOUJEO (Insulin Glargine) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c9561d96-124d-48ca-982f-0aa1575bff36. Date Accessed October 5, 2026.